Inactivation of CDKN2A, through loss of heterozygosity or hypermethylation of its promoter, has been reported in endometriosis and endometrial cancer (Goumenou et al., 2000; Martini et al., 2002; Guida et al., 2009). Here, CDKN2A is linked to endometrial cancer.